Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.

Cancer chemotherapy and pharmacology - 1 Nov 2018

Huang Min, Zhu Hong, Yi Cheng, Yan Juan, Wei Lijia, Yang Xi, Chen Shouchun, Huang Ying

Abstract excerpt

PURPOSE: Pancreatic cancer is a malignant tumor of the digestive system with poor prognosis and high mortality, and the treatment of pancreatic cancer still remains a major challenge. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis selectively in cancer cells while causing virtually no damage to normal cells, which is promising for cancer therapy. However, many primary tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Pancreatic Neoplasms

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Up-Regulation

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 30167846
DOI: 10.1007/s00280-018-3658-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.PMID 30167846Read ↗

TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo.Semantic proximity Read ↗

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Semantic proximity Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

TRAIL as a target in anti-cancer therapy.Semantic proximity Read ↗

Therapeutic applications of TRAIL receptor agonists in cancer and beyondSemantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer CellsSemantic proximity Read ↗

Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.Semantic proximity Read ↗

Directed Change in TNFα Specificity to Create DR5 Antagonists.Semantic proximity Read ↗

TRAIL Promotes Epithelial-to-mesenchymal Transition by Inducing PD-L1 Expression in Esophageal Squamous Cell CarcinomasSemantic proximity Read ↗

Death receptors as targets for anti‐cancer therapySemantic proximity Read ↗

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.